AAPL 182.74 0.1864% MSFT 410.54 0.2932% GOOG 171.16 -1.0521% GOOGL 169.38 -1.092% AMZN 188.0 -0.4026% NVDA 904.12 -0.1568% META 472.6 0.9311% TSLA 174.72 -1.7378% TSM 143.6 1.7646% LLY 775.0 -0.3561% V 277.19 0.2641% AVGO 1325.37 1.7082% JPM 195.65 2.0339% UNH 503.21 0.4491% NVO 126.69 -0.4714% WMT 60.3 -0.5279% LVMUY 169.84 -0.2174% XOM 116.15 -0.0172% LVMHF 846.814 -0.7252% MA 454.77 0.3774%
Last update at 2024-05-08T20:10:00Z
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Income before tax | 1339.00M | 1504.00M | 1360.00M | 842.00M | 919.00M |
| Minority interest | - | - | - | - | - |
| Net income | 1240.00M | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Selling general administrative | 1634.00M | 1637.00M | 1619.00M | 1496.00M | 1460.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3465.00M | 3722.00M | 3407.00M | 2837.00M | 2805.00M |
| Reconciled depreciation | 271.00M | 317.00M | 321.00M | 308.00M | 238.00M |
| Ebit | 1434.00M | 1618.00M | 1347.00M | 846.00M | 941.00M |
| Ebitda | 1705.00M | 1905.00M | 1762.00M | 1228.00M | 1231.00M |
| Depreciation and amortization | 271.00M | 287.00M | 415.00M | 382.00M | 290.00M |
| Non operating income net other | - | -30.00000M | 94.00M | 74.00M | 52.00M |
| Operating income | 1350.00M | 1618.00M | 1347.00M | 846.00M | 941.00M |
| Other operating expenses | 5483.00M | 5230.00M | 4972.00M | 4493.00M | 4222.00M |
| Interest expense | 95.00M | 84.00M | 81.00M | 78.00M | 74.00M |
| Tax provision | 99.00M | 250.00M | 150.00M | 123.00M | -152.00000M |
| Interest income | 51.00M | 9.00M | 79.00M | 70.00M | 36.00M |
| Net interest income | -44.00000M | -75.00000M | -79.00000M | -70.00000M | -38.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 99.00M | 250.00M | 150.00M | 123.00M | -152.00000M |
| Total revenue | 6833.00M | 6848.00M | 6319.00M | 5339.00M | 5163.00M |
| Total operating expenses | 2115.00M | 2104.00M | 2060.00M | 1991.00M | 1864.00M |
| Cost of revenue | 3368.00M | 3126.00M | 2912.00M | 2502.00M | 2358.00M |
| Total other income expense net | 33.00M | -114.00000M | 13.00M | -4.00000M | -22.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1240.00M | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Net income applicable to common shares | - | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Total assets | 10763.00M | 10516.00M | 10705.00M | 9627.00M | 9452.00M |
| Intangible assets | 475.00M | 821.00M | 981.00M | 831.00M | 1107.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 274.00M | 282.00M | 222.00M | 216.00M | 198.00M |
| Total liab | 4918.00M | 5227.00M | 5316.00M | 4754.00M | 4704.00M |
| Total stockholder equity | 5845.00M | 5289.00M | 5389.00M | 4873.00M | 4748.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 680.00M | 784.00M | 821.00M | 652.00M | 774.00M |
| Common stock | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Capital stock | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Retained earnings | 782.00M | 324.00M | 348.00M | 81.00M | -18.00000M |
| Other liab | - | 633.00M | 879.00M | 876.00M | 833.00M |
| Good will | 3960.00M | 4773.00M | 4956.00M | 4433.00M | 4700.00M |
| Other assets | - | 670.00M | 820.00M | 601.00M | 611.00M |
| Cash | 1590.00M | 1053.00M | 1484.00M | 1441.00M | 1382.00M |
| Cash and equivalents | - | 1053.00M | 1484.00M | 1441.00M | 1382.00M |
| Total current liabilities | 1603.00M | 1861.00M | 1708.00M | 1467.00M | 2080.00M |
| Current deferred revenue | 505.00M | 461.00M | 441.00M | 386.00M | 336.00M |
| Net debt | 1145.00M | 1716.00M | 1245.00M | 918.00M | 1025.00M |
| Short term debt | - | 36.00M | 0.00000M | 75.00M | 616.00M |
| Short long term debt | - | 36.00M | - | 75.00M | 616.00M |
| Short long term debt total | 2735.00M | 2769.00M | 2729.00M | 2359.00M | 2407.00M |
| Other stockholder equity | 5387.00M | 5325.00M | 5320.00M | 5311.00M | 5277.00M |
| Property plant equipment | - | 1100.00M | 945.00M | 845.00M | 850.00M |
| Total current assets | 4186.00M | 3778.00M | 3799.00M | 3415.00M | 3189.00M |
| Long term investments | 164.00M | 195.00M | 185.00M | 158.00M | 102.00M |
| Net tangible assets | - | 516.00M | 433.00M | 440.00M | 48.00M |
| Short term investments | - | 0.00000M | 91.00M | 158.00M | - |
| Net receivables | 1291.00M | 1405.00M | 1172.00M | 1038.00M | 930.00M |
| Long term debt | 2735.00M | 2733.00M | 2729.00M | 2284.00M | 1791.00M |
| Inventory | 1031.00M | 1038.00M | 830.00M | 720.00M | 679.00M |
| Accounts payable | 418.00M | 580.00M | 446.00M | 354.00M | 354.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -327.00000M | -363.00000M | -282.00000M | -522.00000M | -514.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 3.00M | 3.00M | 3.00M | 3.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 324.00M | 348.00M | 81.00M | -18.00000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 708.00M | 670.00M | 820.00M | 776.00M | 611.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6577.00M | 6738.00M | 6906.00M | 6212.00M | 6263.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 2733.00M | 2729.00M | 2284.00M | 1791.00M |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Investments | -310.00000M | 9.00M | -10.00000M | -29.00000M | -26.00000M |
| Change to liabilities | - | 121.00M | 64.00M | 31.00M | 52.00M |
| Total cashflows from investing activities | - | -338.00000M | -749.00000M | -147.00000M | -1590.00000M |
| Net borrowings | - | 26.00M | 356.00M | -45.00000M | 596.00M |
| Total cash from financing activities | -930.00000M | -1372.00000M | -696.00000M | -717.00000M | -299.00000M |
| Change to operating activities | - | -30.00000M | 112.00M | -152.00000M | -26.00000M |
| Net income | 1240.00M | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Change in cash | 537.00M | -434.00000M | 43.00M | 59.00M | -866.00000M |
| Begin period cash flow | 1056.00M | 1490.00M | 1447.00M | 1388.00M | 2254.00M |
| End period cash flow | 1593.00M | 1056.00M | 1490.00M | 1447.00M | 1388.00M |
| Total cash from operating activities | 1772.00M | 1312.00M | 1485.00M | 921.00M | 1021.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 271.00M | 317.00M | 321.00M | 308.00M | 238.00M |
| Other cashflows from investing activities | - | -4.00000M | -5.00000M | 1.00M | -1409.00000M |
| Dividends paid | -265.00000M | -250.00000M | -236.00000M | -222.00000M | -206.00000M |
| Change to inventory | -33.00000M | -248.00000M | -136.00000M | -68.00000M | -36.00000M |
| Change to account receivables | 132.00M | -321.00000M | -128.00000M | -107.00000M | -106.00000M |
| Sale purchase of stock | -575.00000M | -1139.00000M | -788.00000M | -469.00000M | -723.00000M |
| Other cashflows from financing activities | -122.00000M | 1828.00M | -83.00000M | -41.00000M | -24.00000M |
| Change to netincome | - | 219.00M | 42.00M | 247.00M | -149.00000M |
| Capital expenditures | 298.00M | 291.00M | 189.00M | 119.00M | 156.00M |
| Change receivables | - | -321.00000M | -128.00000M | -107.00000M | -106.00000M |
| Cash flows other operating | - | 59.00M | -112.00000M | -209.00000M | -49.00000M |
| Exchange rate changes | - | - | 3.00M | 2.00M | 2.00M |
| Cash and cash equivalents changes | - | -398.00000M | 43.00M | 59.00M | -866.00000M |
| Change in working capital | -116.00000M | -478.00000M | -88.00000M | -296.00000M | -388.00000M |
| Stock based compensation | 111.00M | 125.00M | 110.00M | 83.00M | 72.00M |
| Other non cash items | 322.00M | 86.00M | -82.00000M | 78.00M | 283.00M |
| Free cash flow | 1474.00M | 1021.00M | 1296.00M | 802.00M | 865.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| A Agilent Technologies Inc |
1.53 1.08% | 142.80 | 33.37 | 25.32 | 5.91 | 6.99 | 6.09 | 24.42 |
| TMO Thermo Fisher Scientific Inc |
0.77 0.13% | 573.64 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.79 0.32% | 249.55 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
3.39 0.70% | 487.07 | 55.57 | 53.76 | 12.50 | 34.56 | 12.72 | 38.21 |
| IQV IQVIA Holdings Inc |
-1.26 0.55% | 227.88 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael R. McMullen | CEO, Pres & Director | 1961 |
| Mr. Robert W. McMahon | Sr. VP & CFO | 1969 |
| Mr. Jacob Thaysen | Sr. VP and Pres of Life Sciences & Applied Markets Group | 1975 |
| Mr. Samraat S. Raha | Sr. VP and Pres of Diagnostics & Genomics Group | 1973 |
| Mr. Padraig McDonnell | Sr. VP & Pres of Agilent Cross Lab Group | NA |
| Mr. Rodney Gonsalves | Principal Accounting Officer, VP & Corp. Controller | 1966 |
| Dr. Darlene J. S. Solomon Ph.D. | CTO & Sr. VP | 1959 |
| Mr. Michael Tang | Sr. VP, Gen. Counsel & Sec. | 1974 |
| Mr. Dominique P. Grau | Sr. VP of HR & Global Communications | 1959 |
| Ms. Allison Ballmer | Sr. VP of Strategy & Corp. Devel. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...